Servier Wagers $2.65bn on Edgewise Muscular Dystrophy Drug

Edgewise to sell muscle dystrophy business to Servier for up to $2.65 ...

Servier buys into muscular dystrophy with potentially $2.7B deal

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

Servier to buy Edgewise Therapeutics' muscular dystrophy drug

The deal centers on an experimental drug called sevasemten, and fits with Servier's focus on rare neurological and neuromuscular conditions.

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that it has entered into a...

French pharma giant Servier buys Edgewise muscular dystrophy biz

Edgewise has offloaded its muscular-dystrophy business to Servier in a deal that could eventually be worth as much as $2.65 billion.